Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (NCT04446117)
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.
Who can join: Review the eligibility criteria below.
Location: Exelixis Clinical Site #4 — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (280 Sites)
Showing the first 25 of 280 sites.
- Exelixis Clinical Site #4 — Tucson, Arizona
- Exelixis Clinical Site #42 — Duarte, California
- Exelixis Clinical Site #2 — Fullerton, California
- Exelixis Clinical Site #224 — La Jolla, California
- Exelixis Clinical Site #3 — Marina del Rey, California
- Exelixis Clinical Site #114 — San Diego, California
- Exelixis Clinical Site #125 — Santa Monica, California
- Exelixis Clinical Site #245 — Stanford, California
- Exelixis Clinical Site #91 — Aurora, Colorado
- Exelixis Clinical Site #14 — Denver, Colorado
- Yale University School of Medicine — New Haven, Connecticut
- Yale University, School of Medicine — New Haven, Connecticut
- Exelixis Clinical Site #108 — Miami, Florida
- Winship Cancer Institute of Emory University — Atlanta, Georgia
- Exelixis Clinical Site #215 — Westwood, Kansas
- Exelixis Clinical Site #242 — Louisville, Kentucky
- Exelixis Clinical Site #6 — Baltimore, Maryland
- Non-participating Site — Detroit, Michigan
- Exelixis Clinical Site #203 — Rochester, Minnesota
- Exelixis Clinical Site #19 — Omaha, Nebraska
- Exelixis Clinical Site #144 — Las Vegas, Nevada
- Exelixis Clinical Site #123 — East Brunswick, New Jersey
- Non-participating Site — Lawrenceville, New Jersey
- Weill Cornell Medical College — New York, New York
- Exelixis Clinical Site #198 — The Bronx, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Prostate Cancer
- Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC — Boston, Massachusetts
- PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer — Boston, Massachusetts
- Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer — Detroit, Michigan
- Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer — Basking Ridge, New Jersey
- Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers — New York, New York
Explore by condition: All Metastatic Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.